Carrick announces first patient dosed in trial of samuraciclib, vepdegestrant

Carrick Therapeutics announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib, an investigational oral and first-in-class inhibitor of CDK7, and vepdegestrant, an investigational oral PROTAC estrogen receptor degrader, being jointly developed by Arvinas (ARVN) and Pfizer ( PFE) in women with ER+, HER2- metastatic breast cancer who have previously received a CDK4/6 inhibitor. “We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “We believe there is great potential for this combination treatment, based on the encouraging initial clinical trial data for vepdegestrant and Pfizer’s deep expertise in developing treatments for breast cancer.”